MAP PHARMACEUTICALS, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 81 rows in 2013. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2013-03-01: Reporting owner MCPHERRON MATTHEW V; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2013-03-01: Reporting owner MCPHERRON MATTHEW V; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2013-03-01: Reporting owner MCPHERRON MATTHEW V; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2013-03-01: Reporting owner MCPHERRON MATTHEW V; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2013-03-01 | MCPHERRON MATTHEW V Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,500 0 owned after | $12.19 exercise price | 2013-03-05 | |
| 2013-03-01 | MCPHERRON MATTHEW V Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,500 0 owned after | $3.18 exercise price | 2013-03-05 | |
| 2013-03-01 | MCPHERRON MATTHEW V Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,500 0 owned after | $14.77 exercise price | 2013-03-05 | |
| 2013-03-01 | MCPHERRON MATTHEW V Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,500 0 owned after | $16.47 exercise price | 2013-03-05 | |
| 2013-03-01 | MCPHERRON MATTHEW V Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $11.69 exercise price | 2013-03-05 | |
| 2013-03-01 | CHAI CHRISTOPHER Y Officer (SVP, Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −23,122 0 owned after | $0.74 exercise price | 2013-03-04 | |
| 2013-03-01 | CHAI CHRISTOPHER Y Officer (SVP, Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −11,299 0 owned after | $3.36 exercise price | 2013-03-04 | |
| 2013-03-01 | CHAI CHRISTOPHER Y Officer (SVP, Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −47,296 0 owned after | $6.39 exercise price | 2013-03-04 | |
| 2013-03-01 | CHAI CHRISTOPHER Y Officer (SVP, Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −60,000 0 owned after | $13.12 exercise price | 2013-03-04 | |
| 2013-03-01 | CHAI CHRISTOPHER Y Officer (SVP, Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −75,000 0 owned after | $10.37 exercise price | 2013-03-04 | |
| 2013-03-01 | CHAI CHRISTOPHER Y Officer (SVP, Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −55,000 0 owned after | $16.19 exercise price | 2013-03-04 | |
| 2013-03-01 | CHAI CHRISTOPHER Y Officer (SVP, Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −27,500 0 owned after | $16.15 exercise price | 2013-03-04 | |
| 2013-03-01 | CHAI CHRISTOPHER Y Officer (SVP, Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −32,500 0 owned after | $14.09 exercise price | 2013-03-04 | |
| 2013-03-01 | NELSON TIMOTHY S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −132,549 0 owned after | $0.64 exercise price | 2013-03-04 | |
| 2013-03-01 | NELSON TIMOTHY S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −71,509 0 owned after | $0.64 exercise price | 2013-03-04 | |
| 2013-03-01 | NELSON TIMOTHY S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −179,176 0 owned after | $0.74 exercise price | 2013-03-04 | |
| 2013-03-01 | NELSON TIMOTHY S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −121,468 0 owned after | $3.36 exercise price | 2013-03-04 | |
| 2013-03-01 | NELSON TIMOTHY S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −180,790 0 owned after | $6.39 exercise price | 2013-03-04 | |
| 2013-03-01 | NELSON TIMOTHY S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −160,000 0 owned after | $13.12 exercise price | 2013-03-04 | |
| 2013-03-01 | NELSON TIMOTHY S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −175,000 0 owned after | $10.37 exercise price | 2013-03-04 | |
| 2013-03-01 | NELSON TIMOTHY S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −100,000 0 owned after | $16.19 exercise price | 2013-03-04 | |
| 2013-03-01 | NELSON TIMOTHY S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −200,000 0 owned after | $16.15 exercise price | 2013-03-04 | |
| 2013-03-01 | NELSON TIMOTHY S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −112,500 0 owned after | $14.09 exercise price | 2013-03-04 | |
| 2013-03-01 | ARMER THOMAS A Director, Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −40,847 0 owned after | $3.36 exercise price | 2013-03-04 | |
| 2013-03-01 | ARMER THOMAS A Director, Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −22,526 0 owned after | $6.39 exercise price | 2013-03-04 | |
| 2013-03-01 | ARMER THOMAS A Director, Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,000 0 owned after | $13.12 exercise price | 2013-03-04 | |
| 2013-03-01 | ARMER THOMAS A Director, Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −75,000 0 owned after | $10.37 exercise price | 2013-03-04 | |
| 2013-03-01 | ARMER THOMAS A Director, Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,000 0 owned after | $16.19 exercise price | 2013-03-04 | |
| 2013-03-01 | ARMER THOMAS A Director, Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −27,500 0 owned after | $16.15 exercise price | 2013-03-04 | |
| 2013-03-01 | ARMER THOMAS A Director, Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −32,500 0 owned after | $14.09 exercise price | 2013-03-04 | |
| 2013-03-01 | Friedman Charlene A Officer (SVP, Gen Counsel & Sec) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −74,744 0 owned after | $12.37 exercise price | 2013-03-04 | |
| 2013-03-01 | Friedman Charlene A Officer (SVP, Gen Counsel & Sec) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −30,000 0 owned after | $13.12 exercise price | 2013-03-04 | |
| 2013-03-01 | Friedman Charlene A Officer (SVP, Gen Counsel & Sec) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,805 0 owned after | $10.37 exercise price | 2013-03-04 | |
| 2013-03-01 | Friedman Charlene A Officer (SVP, Gen Counsel & Sec) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −55,000 0 owned after | $16.19 exercise price | 2013-03-04 | |
| 2013-03-01 | Friedman Charlene A Officer (SVP, Gen Counsel & Sec) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −27,500 0 owned after | $16.15 exercise price | 2013-03-04 | |
| 2013-03-01 | Friedman Charlene A Officer (SVP, Gen Counsel & Sec) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −32,500 0 owned after | $14.09 exercise price | 2013-03-04 | |
| 2013-03-01 | GIANAKAKOS ANASTASIOS Officer (SVP, Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −40,000 0 owned after | $13.12 exercise price | 2013-03-04 | |
| 2013-03-01 | GIANAKAKOS ANASTASIOS Officer (SVP, Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,000 0 owned after | $10.37 exercise price | 2013-03-04 | |
| 2013-03-01 | GIANAKAKOS ANASTASIOS Officer (SVP, Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −45,000 0 owned after | $16.19 exercise price | 2013-03-04 | |
| 2013-03-01 | GIANAKAKOS ANASTASIOS Officer (SVP, Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −27,500 0 owned after | $16.15 exercise price | 2013-03-04 | |
| 2013-03-01 | GIANAKAKOS ANASTASIOS Officer (SVP, Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −32,500 0 owned after | $14.09 exercise price | 2013-03-04 | |
| 2013-03-01 | KELLERMAN DONALD J Officer (SVP,Clinical Dev & Med Affairs) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −61,450 0 owned after | $9.20 exercise price | 2013-03-04 | |
| 2013-03-01 | KELLERMAN DONALD J Officer (SVP,Clinical Dev & Med Affairs) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −29,500 0 owned after | $10.37 exercise price | 2013-03-04 | |
| 2013-03-01 | KELLERMAN DONALD J Officer (SVP,Clinical Dev & Med Affairs) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −55,000 0 owned after | $16.19 exercise price | 2013-03-04 | |
| 2013-03-01 | KELLERMAN DONALD J Officer (SVP,Clinical Dev & Med Affairs) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −27,500 0 owned after | $16.15 exercise price | 2013-03-04 | |
| 2013-03-01 | KELLERMAN DONALD J Officer (SVP,Clinical Dev & Med Affairs) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −32,500 0 owned after | $14.09 exercise price | 2013-03-04 | |
| 2013-03-01 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −1,648 0 owned after | $3.36 exercise price | 2013-03-04 | |
| 2013-03-01 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −1,589 0 owned after | $6.39 exercise price | 2013-03-04 | |
| 2013-03-01 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $13.12 exercise price | 2013-03-04 | |
| 2013-03-01 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −51,500 0 owned after | $10.37 exercise price | 2013-03-04 | |
| 2013-03-01 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −35,000 0 owned after | $16.19 exercise price | 2013-03-04 | |
| 2013-03-01 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −21,000 0 owned after | $16.15 exercise price | 2013-03-04 | |
| 2013-03-01 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −13,750 0 owned after | $15.38 exercise price | 2013-03-04 | |
| 2013-03-01 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −32,500 0 owned after | $14.09 exercise price | 2013-03-04 | |
| 2013-03-01 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −248 0 owned after | $3.36 exercise price | 2013-03-04 | |
| 2013-03-01 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −4,237 0 owned after | $6.39 exercise price | 2013-03-04 | |
| 2013-03-01 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −2,500 0 owned after | $13.12 exercise price | 2013-03-04 | |
| 2013-03-01 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −5,000 0 owned after | $10.37 exercise price | 2013-03-04 | |
| 2013-03-01 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −4,375 0 owned after | $16.19 exercise price | 2013-03-04 | |
| 2013-03-01 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −1,800 0 owned after | $16.15 exercise price | 2013-03-04 | |
| 2013-03-01 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −3,000 0 owned after | $14.09 exercise price | 2013-03-04 | |
| 2013-03-01 | Wolff Henry Ward Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −30,000 0 owned after | $12.74 exercise price | 2013-03-04 | |
| 2013-03-01 | Wolff Henry Ward Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,500 0 owned after | $3.18 exercise price | 2013-03-04 | |
| 2013-03-01 | Wolff Henry Ward Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,500 0 owned after | $14.77 exercise price | 2013-03-04 | |
| 2013-03-01 | Wolff Henry Ward Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,500 0 owned after | $16.47 exercise price | 2013-03-04 | |
| 2013-03-01 | Wolff Henry Ward Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $11.69 exercise price | 2013-03-04 | |
| 2013-03-01 | WARD SCOTT R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −30,000 0 owned after | $8.98 exercise price | 2013-03-04 | |
| 2013-03-01 | WARD SCOTT R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,500 0 owned after | $3.18 exercise price | 2013-03-04 | |
| 2013-03-01 | WARD SCOTT R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,500 0 owned after | $14.77 exercise price | 2013-03-04 | |
| 2013-03-01 | WARD SCOTT R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,500 0 owned after | $16.47 exercise price | 2013-03-04 | |
| 2013-03-01 | WARD SCOTT R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $11.69 exercise price | 2013-03-04 | |
| 2013-03-01 | OSHEA WILLIAM J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −20,000 0 owned after | $13.79 exercise price | 2013-03-04 | |
| 2013-03-01 | HENWOOD GERALDINE Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,500 0 owned after | $14.77 exercise price | 2013-03-04 | |
| 2013-03-01 | HENWOOD GERALDINE Director | 4 | Stock Option (Right to Buy Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,500 0 owned after | $16.47 exercise price | 2013-03-04 | |
| 2013-03-01 | HENWOOD GERALDINE Director | 4 | Stock Option (Right to Buy Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −5,000 0 owned after | $11.69 exercise price | 2013-03-04 | |
| 2013-02-28 | GIANAKAKOS ANASTASIOS Officer (SVP, Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +20,000 50,000 owned after | $10.37 exercise price | 2013-03-04 | |
| 2013-02-28 | HENWOOD GERALDINE Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 5,000 owned after | $11.69 exercise price | 2013-03-04 | |
| 2013-02-28 | HENWOOD GERALDINE Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 0 owned after | $12.19 exercise price | 2013-03-04 | |
| 2013-01-23 | ARMER THOMAS A Director, Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −39,620 0 owned after | $6.39 exercise price | 2013-01-25 | |
| 2013-01-23 | GIANAKAKOS ANASTASIOS Officer (SVP, Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −30,000 57,244 owned after | $10.37 exercise price | 2013-01-25 | |
| 2013-01-23 | NELSON TIMOTHY S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −80,000 132,549 owned after | $0.64 exercise price | 2013-01-25 |